Exhibit 13.1
Certification by the Principal Executive Officer and Principal Financial Officer pursuant to
18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Annual Report on Form 20-F of Immunocore Holdings plc (the “Company”) for the fiscal year ended December 31, 2022 as
filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Bahija Jallal, Chief Executive Officer of the Company and Brian Di Donato, Chief Financial Officer
of the Company, pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, each hereby certifies that, to the best of her or his knowledge:
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date: March 1, 2023
| |
/s/ Bahija Jallal, Ph.D.
|
|
| |
Chief Executive Officer
|
|
| |
(Principal Executive Officer)
|
|
| |
/s/ Brian Di Donato
|
|
| |
Chief Financial Officer
|
|
| |
(Principal Financial Officer)
|
|
This certification accompanies the Form 20-F to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by
reference into any filing of Immunocore Holdings plc under the Securities Exchange Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 20-F), irrespective of any general
incorporation language contained in such filing.